Kestra Advisory Services LLC Has $1.33 Million Stake in GSK PLC Sponsored ADR $GSK

Key Points

• Kestra Advisory Services LLC reduced its stake in GSK PLC Sponsored ADR by 28.1%, owning 34,196 shares worth approximately $1.33 million at the end of the first quarter.
• Several institutional investors, including HHM Wealth Advisors LLC and Cary Street Partners Investment Advisory LLC, significantly increased their stakes in GSK during the same period.
• GSK's latest quarterly earnings reported a profit of $1.23 per share, exceeding estimates, and the company also declared a quarterly dividend of $0.4206, resulting in a 4.2% annualized dividend yield.

Kestra Advisory Services LLC decreased its position in GSK PLC Sponsored ADR (NYSE:GSK - Free Report) by 28.1% in the first quarter, according to its most recent 13F filing with the SEC. The firm owned 34,196 shares of the pharmaceutical company's stock after selling 13,391 shares during the period. Kestra Advisory Services LLC's holdings in GSK were worth $1,325,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. HHM Wealth Advisors LLC boosted its stake in GSK by 222.2% in the 1st quarter. HHM Wealth Advisors LLC now owns 667 shares of the pharmaceutical company's stock worth $26,000 after purchasing an additional 460 shares during the period. Costello Asset Management INC acquired a new position in GSK in the 1st quarter worth approximately $31,000. Richardson Financial Services Inc. boosted its stake in GSK by 127.9% in the 1st quarter. Richardson Financial Services Inc. now owns 841 shares of the pharmaceutical company's stock worth $33,000 after purchasing an additional 472 shares during the period. Olde Wealth Management LLC acquired a new position in GSK in the 1st quarter worth approximately $36,000. Finally, Cary Street Partners Investment Advisory LLC boosted its stake in GSK by 525.9% in the 1st quarter. Cary Street Partners Investment Advisory LLC now owns 1,014 shares of the pharmaceutical company's stock worth $39,000 after purchasing an additional 852 shares during the period. Institutional investors and hedge funds own 15.74% of the company's stock.

Analyst Ratings Changes

A number of research firms recently commented on GSK. Wall Street Zen raised shares of GSK from a "hold" rating to a "buy" rating in a research note on Sunday, August 3rd. Berenberg Bank reiterated a "hold" rating on shares of GSK in a research report on Tuesday, June 3rd. Six equities research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Reduce" and an average price target of $37.38.

GSK Stock Up 0.6%

GSK stock opened at $39.68 on Monday. GSK PLC Sponsored ADR has a 12-month low of $31.72 and a 12-month high of $44.26. The company has a quick ratio of 0.57, a current ratio of 0.87 and a debt-to-equity ratio of 1.07. The company has a market cap of $80.82 billion, a price-to-earnings ratio of 18.37, a PEG ratio of 1.72 and a beta of 0.53. The company has a 50 day moving average of $38.40 and a two-hundred day moving average of $38.25.

GSK (NYSE:GSK - Get Free Report) last released its quarterly earnings results on Wednesday, July 30th. The pharmaceutical company reported $1.23 earnings per share for the quarter, beating analysts' consensus estimates of $1.12 by $0.11. The business had revenue of $10.64 billion for the quarter, compared to the consensus estimate of $7.92 billion. GSK had a net margin of 10.81% and a return on equity of 49.22%. GSK's revenue for the quarter was up 1.3% on a year-over-year basis. During the same quarter last year, the firm earned $0.43 EPS. GSK has set its FY 2025 guidance at 4.590-4.590 EPS. On average, equities analysts anticipate that GSK PLC Sponsored ADR will post 4.14 earnings per share for the current fiscal year.

GSK Cuts Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, October 9th. Stockholders of record on Friday, August 15th will be issued a dividend of $0.4206 per share. The ex-dividend date is Friday, August 15th. This represents a $1.68 dividend on an annualized basis and a dividend yield of 4.2%. GSK's dividend payout ratio (DPR) is currently 77.78%.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.